Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT04956640
Registration number
NCT04956640
Ethics application status
Date submitted
2/07/2021
Date registered
9/07/2021
Date last updated
24/05/2024
Titles & IDs
Public title
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Query!
Scientific title
A Phase 1/2 Study of LY3537982 in Patients With KRAS G12C-Mutant Advanced Solid Tumors
Query!
Secondary ID [1]
0
0
2021-000595-12
Query!
Secondary ID [2]
0
0
LOXO-RAS-20001
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Carcinoma, Non-Small-Cell Lung
0
0
Query!
Colorectal Neoplasms
0
0
Query!
Endometrial Neoplasms
0
0
Query!
Ovarian Neoplasms
0
0
Query!
Pancreatic Neoplasms
0
0
Query!
Biliary Tract Neoplasms
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Bowel - Back passage (rectum) or large bowel (colon)
Query!
Cancer
0
0
0
0
Query!
Lung - Non small cell
Query!
Cancer
0
0
0
0
Query!
Pancreatic
Query!
Cancer
0
0
0
0
Query!
Ovarian and primary peritoneal
Query!
Cancer
0
0
0
0
Query!
Womb (Uterine or endometrial cancer)
Query!
Cancer
0
0
0
0
Query!
Biliary tree (gall bladder and bile duct)
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - LY3537982
Treatment: Drugs - Pembrolizumab
Treatment: Drugs - Cetuximab
Treatment: Drugs - Pemetrexed
Treatment: Drugs - Cisplatin
Treatment: Drugs - Carboplatin
Experimental: LY3537982 (Dose Escalation) - LY3537982 administered orally.
Experimental: LY3537982 (Dose Expansion) - LY3537982 administered orally either alone or with another investigational agent.
Experimental: LY3537982 (Dose Optimization) - LY3537982 administered orally either alone or with another investigational agent
Treatment: Drugs: LY3537982
Oral
Treatment: Drugs: Pembrolizumab
Intravenous
Treatment: Drugs: Cetuximab
Intravenous
Treatment: Drugs: Pemetrexed
Intravenous
Treatment: Drugs: Cisplatin
Intravenous
Treatment: Drugs: Carboplatin
Intravenous
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Phase 1a: To determine the recommended phase 2 dose (RP2D) of LY3537982 monotherapy
Query!
Assessment method [1]
0
0
Measured by the number of patients with dose-limiting toxicities (DLTs)
Query!
Timepoint [1]
0
0
Cycle 1 (21 Days)
Query!
Primary outcome [2]
0
0
Phase 1b: To assess the safety and tolerability of LY3537982 when administered alone or in combination with other investigational agents
Query!
Assessment method [2]
0
0
Measured by the number of patients with dose-limiting toxicities (DLTs)
Query!
Timepoint [2]
0
0
Cycle 1 (21 Days)
Query!
Primary outcome [3]
0
0
Phase 1b: To determine the optimal dose of LY3537982 to be administered to treatment-naïve participants with advanced NSCLC in combination with pembrolizumab
Query!
Assessment method [3]
0
0
Measured by TEAEs
Query!
Timepoint [3]
0
0
Estimated up to 2 years
Query!
Primary outcome [4]
0
0
To determine the optimal dose of LY3537982 to be administered to participants who have received at least one prior oxaliplatin- or irinotecan-containing regimen for advanced or metastatic CRC in combination with cetuximab
Query!
Assessment method [4]
0
0
Query!
Timepoint [4]
0
0
Estimated up to 2 years
Query!
Primary outcome [5]
0
0
To assess the antitumor activity of LY3537982 monotherapy in participants with advanced pancreatic cancer with KRAS G12C mutation
Query!
Assessment method [5]
0
0
Query!
Timepoint [5]
0
0
Estimated up to 2 years
Query!
Secondary outcome [1]
0
0
To assess preliminary antitumor activity of LY3537982 when administered alone or in combination with other investigational agents: Objective response rate (ORR)
Query!
Assessment method [1]
0
0
ORR
Query!
Timepoint [1]
0
0
Estimated up to 2 years
Query!
Secondary outcome [2]
0
0
To assess the preliminary antitumor activity of LY3537982 when administered alone or in combination with other investigational agents: Duration of Response (DOR)
Query!
Assessment method [2]
0
0
DOR
Query!
Timepoint [2]
0
0
Estimated up to 2 years
Query!
Secondary outcome [3]
0
0
To assess the preliminary antitumor activity of LY3537982 when administered alone or in combination with other investigational agents: Best Overall Response (BOR)
Query!
Assessment method [3]
0
0
BOR
Query!
Timepoint [3]
0
0
Estimated up to 2 years
Query!
Secondary outcome [4]
0
0
To assess the preliminary antitumor activity of LY3537982 when administered alone or in combination with other investigational agents: Time to response (TTR)
Query!
Assessment method [4]
0
0
TTR
Query!
Timepoint [4]
0
0
Estimated up to 2 years
Query!
Secondary outcome [5]
0
0
To assess the preliminary antitumor activity of LY3537982 when administered alone or in combination with other investigational agents: Disease control rate (DCR)
Query!
Assessment method [5]
0
0
DCR
Query!
Timepoint [5]
0
0
Estimated up to 2 years
Query!
Secondary outcome [6]
0
0
To assess the preliminary antitumor activity of LY3537982 when administered alone or in combination with other investigational agents: Progression-free survival (PFS)
Query!
Assessment method [6]
0
0
PFS
Query!
Timepoint [6]
0
0
Estimated up to 2 years
Query!
Secondary outcome [7]
0
0
To assess the preliminary antitumor activity of LY3537982 when administered alone or in combination with other investigational agents: Overall survival (OS)
Query!
Assessment method [7]
0
0
OS
Query!
Timepoint [7]
0
0
Estimated up to 2 years
Query!
Secondary outcome [8]
0
0
To assess the preliminary antitumor activity of LY3537982 when administered alone or in combination with other investigational agents: Intracranial DOR based on modified RECIST v1.1 (Certain arms of the study only)
Query!
Assessment method [8]
0
0
Intracranial DOR
Query!
Timepoint [8]
0
0
Estimated up to 2 years
Query!
Secondary outcome [9]
0
0
To assess the preliminary antitumor activity of LY3537982 when administered alone or in combination with other investigational agents: Whole-body ORR based on RECIST v1.1 and modified RECIST v1.1 (Certain arms of the study only)
Query!
Assessment method [9]
0
0
Whole-body ORR
Query!
Timepoint [9]
0
0
Estimated up to 2 years
Query!
Secondary outcome [10]
0
0
To characterize the pharmacokinetics (PK) properties of LY3537982: Area under the plasma concentration versus time curve (AUC)
Query!
Assessment method [10]
0
0
PK: AUC of LY3537982
Query!
Timepoint [10]
0
0
Predose estimated up to 2 years
Query!
Secondary outcome [11]
0
0
To characterize the PK properties of LY3537982: Maximum drug concentration (Cmax)
Query!
Assessment method [11]
0
0
PK: Cmax of LY3537982
Query!
Timepoint [11]
0
0
Predose estimated up to 2 years
Query!
Eligibility
Key inclusion criteria
- Patients have measurable disease per Response Evaluation Criteria in Solid Tumors
version 1.1 (RECIST v1.1).
- Patients must have disease with evidence of KRAS G12C mutation in tumor tissue or
circulating tumor deoxyribonucleic acid (DNA).
- Participants must have a histological or a cytologically proven diagnosis of locally
advanced, unresectable, and/or metastatic cancer and meet cohort-specific criteria.
- Have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
- Have adequate organ function.
- Have discontinued all previous treatments for cancer with resolution of any
significant ongoing adverse events (AEs), (except in certain scenarios).
- Must be able to swallow capsule/tablet.
- Agree and adhere to contraceptive use, if applicable.
- For some parts of the study, (i.e., one of the two arms with LY3537982 in combination
with pembrolizumab and the arm of LY3537982 in combination with pembrolizumab,
pemetrexed, and platinum therapy) histologically or cytologically confirmed Stage
IIIB-IIIC or Stage IV NSCLC that is previously untreated in the advanced/metastatic
setting and not suitable for curative intent radical surgery or radiation therapy.
Previously untreated patients who received adjuvant and neoadjuvant therapy are
eligible if the last dose of the systemic treatment was completed at least 6 months
prior to enrollment. For untreated patients in the arm with LY3537982 in combination
with pembrolizumab noted above, a single cycle of pembrolizumab may be initiated
within 21 days prior to enrollment. For untreated patients in the arm of LY3537982 in
combination with pembrolizumab, pemetrexed, and platinum therapy, a single cycle of
any or all of the drugs other than LY3537982 may be initiated within 21 days prior to
enrollment. Start of study treatment may be delayed to allow sufficient time for
recovery from treatment-related toxicity.
- For one part of the study, participants must have received at least one prior
oxaliplatin- or irinotecan-containing regimen for advanced or metastatic CRC.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Disease suitable for local therapy administered with curative intent.
- Have an active, ongoing, or untreated infection.
- Have a serious pre-existing medical condition(s) that, in the judgment of the
investigator, would preclude participation in this study.
- Have a serious cardiac condition.
- Have a second active primary malignancy or have been diagnosed and/or treated for an
additional malignancy within 3 years prior to enrollment.
- For some parts of the study only: have untreated active central nervous system (CNS)
metastases and/or leptomeningeal disease. Patients with treated CNS metastases are
eligible for this study if their disease is asymptomatic, radiographically stable for
at least 30 days, and they do not require treatment with steroids in the two-week
period prior to study treatment. Patients with active CNS metastases are eligible for
one part of the study.
- Have received prior treatment with any KRAS G12C small molecule inhibitor, except in
certain scenarios where such prior therapy is allowed as per protocol.
- The following patients will be excluded from some parts of the study:
- Experienced certain serious side effects with prior immunotherapy.
- Have an active autoimmune disease that has required systemic anti-autoimmune
treatment in the past 2 years.
- Have received a live vaccine within 30 days prior to the first dose of study
drug.
- Pregnant, breastfeeding, or expecting to conceive or father children within the
projected duration of the trial through 180 days after the last dose of study
medication.
- Known allergic reaction against any of the components of the study treatments.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Other
Query!
Other design features
Query!
Phase
Phase 1/Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
19/07/2021
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
1/02/2026
Query!
Actual
Query!
Sample size
Target
550
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
NSW,SA,VIC,WA
Query!
Recruitment hospital [1]
0
0
Royal North Shore Hospital - St Leonards
Query!
Recruitment hospital [2]
0
0
St Vincent's Hospital Sydney - Sydney
Query!
Recruitment hospital [3]
0
0
Cancer Research SA - Adelaide
Query!
Recruitment hospital [4]
0
0
Peninsula and Southeast Oncology - Frankston
Query!
Recruitment hospital [5]
0
0
Linear Clinical Research - Nedlands
Query!
Recruitment postcode(s) [1]
0
0
2065 - St Leonards
Query!
Recruitment postcode(s) [2]
0
0
2010 - Sydney
Query!
Recruitment postcode(s) [3]
0
0
5000 - Adelaide
Query!
Recruitment postcode(s) [4]
0
0
3199 - Frankston
Query!
Recruitment postcode(s) [5]
0
0
6009 - Nedlands
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Connecticut
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Florida
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Indiana
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Louisiana
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Massachusetts
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
New Hampshire
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
New York
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
North Carolina
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Pennsylvania
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Tennessee
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Texas
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Utah
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Virginia
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Wisconsin
Query!
Country [17]
0
0
Canada
Query!
State/province [17]
0
0
Alberta
Query!
Country [18]
0
0
Canada
Query!
State/province [18]
0
0
Ontario
Query!
Country [19]
0
0
France
Query!
State/province [19]
0
0
Aquitaine
Query!
Country [20]
0
0
France
Query!
State/province [20]
0
0
Rhône-Alpes
Query!
Country [21]
0
0
France
Query!
State/province [21]
0
0
Montpellier Cedex 5
Query!
Country [22]
0
0
France
Query!
State/province [22]
0
0
Paris CEDEX 05
Query!
Country [23]
0
0
France
Query!
State/province [23]
0
0
Toulouse cedex
Query!
Country [24]
0
0
France
Query!
State/province [24]
0
0
Villejuif Cedex
Query!
Country [25]
0
0
Japan
Query!
State/province [25]
0
0
Aichi
Query!
Country [26]
0
0
Japan
Query!
State/province [26]
0
0
Chiba
Query!
Country [27]
0
0
Japan
Query!
State/province [27]
0
0
Hokkaido
Query!
Country [28]
0
0
Japan
Query!
State/province [28]
0
0
Ishikawa
Query!
Country [29]
0
0
Japan
Query!
State/province [29]
0
0
Tokyo
Query!
Country [30]
0
0
Japan
Query!
State/province [30]
0
0
Wakayama
Query!
Country [31]
0
0
Korea, Republic of
Query!
State/province [31]
0
0
Gyeonggi-do
Query!
Country [32]
0
0
Korea, Republic of
Query!
State/province [32]
0
0
Jeonranamdo
Query!
Country [33]
0
0
Korea, Republic of
Query!
State/province [33]
0
0
Korea
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Eli Lilly and Company
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/Industry
Query!
Name [1]
0
0
Loxo Oncology, Inc.
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Other collaborator category [2]
0
0
Commercial sector/Industry
Query!
Name [2]
0
0
Merck Sharp & Dohme LLC
Query!
Address [2]
0
0
Query!
Country [2]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to find out whether the study drug, LY3537982, is safe and
effective in cancer patients who have a specific genetic mutation (KRAS G12C). Patients must
have already received or were not able to tolerate the standard of care, except for specific
groups who have not had cancer treatment. The study will last up to approximately 4 years.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT04956640
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Melinda Willard, PhD
Query!
Address
0
0
Loxo Oncology, Inc.
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Patient Advocacy
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
855-569-6305
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT04956640
Download to PDF